--- title: 'Research Scientist I/II, Bioanalytical Sciences & Assay Development at Iambic Therapeutics, Inc' canonical: 'https://feeny.ai/job/research-scientist-i-ii-bioanalytical-sciences-assay-development-iambic-z1xnw171hxqv' type: 'job' last_seen: '2026-09-09' --- # Research Scientist I/II, Bioanalytical Sciences & Assay Development at Iambic Therapeutics, Inc - **Company:** Iambic Therapeutics, Inc - **Location:** San Diego, CA - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-08-31 - **Last confirmed live:** 2026-09-09 - **Apply:** https://jobs.ashbyhq.com/iambic-therapeutics/4a04c67c-1be5-4109-8f9f-b3e8dd818e37 ## Job description ## JOB SUMMARY We are seeking a highly motivated Research Scientist, Bioanalytical Sciences & Assay Development to join our drug discovery team. This scientist will develop and implement mass spectrometry-based assays and bioanalytical workflows supporting Hit Identification (HitID), ADME/DMPK characterization, and physicochemical property assessment. A key focus will be the development and application of MS-based screening approaches for HitID, including Affinity Selection Mass Spectrometry (ASMS) and other MS-based capabilities. The ideal candidate will have a strong foundation in bioanalytical science, mass spectrometry, and assay development, with the ability to develop robust and scalable assays for small-molecule drug discovery. This scientist will work at the interface of experimental science, automation, and AI-driven molecular design, generating high-quality data that inform compound optimization and enable rapid design–make–test–learn cycles. This position will be based in our San Diego Headquarters. ## KEY RESPONSIBILITIES - Develop and implement MS-based assays and screening workflows for HitID, including ASMS and other MS-based approaches. - Develop fit-for-purpose bioanalytical and biochemical assays supporting screening, hit confirmation, and compound characterization. - Develop and execute in vitro ADME/DMPK assays, including metabolic stability, permeability, protein binding, and related endpoints. - Develop physicochemical property assays, including solubility, logD/lipophilicity, ePSA, and related measurements. - Develop and optimize LC-MS/MS bioanalytical methods and troubleshoot assay performance, sensitivity, selectivity, matrix effects, and reproducibility. - Develop automated and high-throughput assay workflows to improve capacity, turnaround time, and data quality. - Support operation and troubleshooting of MS and LC/MS instrumentation and associated laboratory automation. - Generate high-quality experimental datasets that support AI/ML-driven compound design and optimization. - Collaborate with biology, screening/HitID, medicinal chemistry, DMPK, and computational/AI teams to design assay strategies and translate experimental results into actionable insights. - Evaluate new assay technologies, MS methodologies, automation solutions, and data workflows to expand drug discovery capabilities. ## QUALIFICATIONS - Ph.D. in Bioanalytical Chemistry, Mass Spectrometry, Chemical Biology, Drug Metabolism/Pharmacokinetics, Pharmaceutical Sciences, Biochemistry, or a related discipline, with approximately 0–5 years of relevant experience; or an M.S. with significant relevant industry experience. - Strong foundation in mass spectrometry, bioanalytical science, and assay development, preferably with hands-on LC-MS/MS experience. - Demonstrated experience developing, optimizing, and troubleshooting bioanalytical, biochemical, or screening assays. - Strong understanding of quantitative assay design, experimental controls, data quality, and troubleshooting. - Strong scientific problem-solving and collaboration skills, with an interest in connecting experimental data with AI/ML-enabled drug discovery and molecular design. ## PREFERRED QUALIFICATIONS - Experience with MS-based screening or HitID approaches, including ASMS or related technologies, is highly desirable. - Experience with in vitro ADME/DMPK and/or physicochemical property assays such as solubility, logD, and ePSA is preferred. - Experience with SCIEX, Agilent, Thermo, or comparable MS/LC-MS platforms is desirable. - Experience with laboratory automation, high-throughput screening/experimentation, or automated data processing is a plus. ## ABOUT IAMBIC THERAPEUTICS Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at iambic.ai http://iambic.ai. ## MISSION & CORE VALUES Our mission is to deliver better medicines through innovations in AI-based discovery technologies. The culture and work at Iambic Therapeutics are profoundly strengthened by the diversity of our people and our differences in background, culture, national origin, religion, sexual orientation, and life experiences. We are committed to building an inclusive environment where a diverse group of talented humans work together to discover therapeutics and create technologies. ## PAY AND BENEFITS We offer industry leading competitive pay, company paid healthcare, flexible spending accounts, voluntary life insurance, 401K matching, and uncapped vacation to our team. We are in a brand-new state-of-the art facility in beautiful San Diego with an onsite gym, dining, and easy access to great places to live and play. ## About Iambic Therapeutics, Inc ## Company Overview - **One-liner**: Iambic Therapeutics is a clinical‑stage biotechnology company that uses an AI‑driven platform to discover and develop novel small‑molecule medicines for oncology and other diseases. - **Entity Type**: Private (late‑stage venture‑backed) - **Headquarters**: San Diego, California, United States - **Founded**: 2020 - **Founders**: Not explicitly named in available sources; leadership includes a Co‑Founder & CEO and a Co‑Founder & CTO. ## Core Business - **Primary industries**: Biotechnology, AI‑powered drug discovery, oncology therapeutics - **Target customers**: B2B partnerships with pharmaceutical companies (e.g., Bayer) and, ultimately, patients through a wholly‑owned pipeline of clinical‑stage candidates - **Mission**: *“Better technology for better medicines”* – using machine learning and automation to transform the creation of new therapeutics ## Products & Services - **Enchant Platform**: A multi‑modal transformer AI that breaks down data barriers between preclinical and clinical R&D, enabling rapid molecular design. - **NeuralPLexer**: A co‑folding AI technology that predicts protein‑ligand structures to guide drug design. - **Automated High‑Throughput Experimentation**: AI‑driven robotics that generate new biological data from novel molecular designs on a weekly cadence. - **IAM1363** (HER2 inhibitor): A highly selective, brain‑penetrant tyrosine kinase inhibitor for HER2‑driven cancers; currently in Phase 1b clinical studies. - **IAM‑C1** (CDK2/4 dual inhibitor): A potential first‑in‑class selective inhibitor for HR+/HER2‑ metastatic breast cancer (preclinical). - **IAM‑K1** (KIF18A inhibitor): A potential best‑in‑class allosteric inhibitor for triple‑negative breast cancer, ovarian cancer, and other solid tumors (preclinical). - **Undisclosed programs**: Additional wholly‑owned candidates across multiple target classes and mechanisms. ## Market Standing - **Valuation**: Not publicly disclosed - **Key Metric**: **Total funding** – $330.8 M (including a $100 M Series B in Oct 2023, a $50 M Series B extension in Apr 2024 led by EXOR N.V. and Mubadala Capital, and a $127.8 M venture round in Nov 2025) - **Notable Investors/Partners**: EXOR N.V., Mubadala Capital, Nexus Venture, Bayer (collaboration in AI drug discovery), and a Scientific Advisory Board including Nobel Laureate Frances Arnold (Caltech) - **Growth Signals**: - Headcount of **117** (64.5 % year‑over‑year growth) - Active job postings: **18** (+200 % quarterly, +50 % yearly) - Pipeline advanced from program launch to IND in **2 years** (vs. 6‑year industry average for IAM1363) - Broad platform applicability demonstrated across orthosteric, allosteric, and protein‑protein interaction modalities ## Competitive Advantages - **Speed**: AI‑driven platform can deliver development candidates to clinical trials in roughly one‑third the industry average time. - **Selectivity & Differentiated Profiles**: IAM1363 shows > 5000‑fold selectivity against EGFR, avoiding EGFR‑driven toxicity; IAM‑C1 targets CDK2/4 with a novel selectivity profile. - **Broad Platform Applicability**: Platform has produced leads across diverse protein classes and mechanisms (orthosteric, allosteric, PPI modulators). - **Integration of AI and Drug Hunting**: Tightly integrated team of AI experts and seasoned drug hunters, with a culture of “audacity” that tackles hard chemistry problems. ## Strategic Focus - Advancing the clinical pipeline: IAM1363 Phase 1b, preparing IAM‑C1 and IAM‑K1 for IND‑enabling studies. - Expanding platform partnerships (e.g., Bayer collaboration). - Scaling the organization: actively hiring in ML science, computational chemistry, medicinal chemistry, and clinical operations. - Exploring new therapeutic areas and target classes through the Enchant and NeuralPLexer technologies. ## Why Work Here - **Culture**: Values of **Respect**, **Collaboration**, and **Audacity** – cross‑functional teamwork with resilience and optimism; a flat, high‑trust environment. - **Work Model**: Based in La Jolla/San Diego, CA; the company emphasizes on‑site collaboration for drug‑discovery and lab‑based roles; remote/hybrid policy not explicitly stated. - **Team Growth**: Rapidly scaling (headcount +64 % YoY) with a strong pipeline of open roles in ML, computational chemistry, drug product development, and clinical operations. - **Cutting‑Edge Work**: Opportunity to work at the intersection of frontier AI (large multimodal models, agentic data pipelines) and real‑world drug discovery that reaches patients. - **Leadership & Mentorship**: Advisory board includes Nobel laureate and former NVIDIA AI director; close integration of AI and biology. ## Sources 1. [iambic.ai](https://www.iambic.ai/) – Homepage, platform, and corporate overview 2. [iambic.ai/about](https://www.iambic.ai/about) – Leadership, advisory board, investors 3. [iambic.ai/pipeline](https://www.iambic.ai/pipeline) – Pipeline details (IAM1363, IAM‑C1, IAM‑K1) 4. [iambic.ai/careers](https://www.iambic.ai/careers) – Careers page, values, open positions 5. [linkedin.com/company/iambic-ai](https://www.linkedin.com/company/iambic-ai) – Company stats (headcount 117, $3.4M revenue, $330.8M funding, funding rounds, employee growth) ## Other roles at Iambic Therapeutics, Inc - [Sr Manager, FP&A - Discovery R&D](https://feeny.ai/job/sr-manager-fp-a-discovery-r-d-iambic-therapeutics-inc-san-diego-sznt8xkbx741) — San Diego, CA - [Director/Senior Director, Immunology](https://feeny.ai/job/director-senior-director-immunology-iambic-therapeutics-inc-san-diego-pc8aedpavc67) — San Diego, CA - [Software Engineer — Agentic data pipelines](https://feeny.ai/job/software-engineer-agentic-data-pipelines-iambic-therapeutics-inc-united-states-z1afztyyenvn) — United States - [Principal Medical Writer](https://feeny.ai/job/principal-medical-writer-iambic-therapeutics-inc-united-states-p7p8wv9kdmyd) — United States - [Sr Manager, Quality Systems & Compliance](https://feeny.ai/job/sr-manager-quality-systems-compliance-iambic-therapeutics-inc-united-states-vsh166q5vj7e) — United States - [Machine Learning Scientist – Clinical Prediction](https://feeny.ai/job/machine-learning-scientist-clinical-prediction-iambic-therapeutics-inc-boston-r8b4amskssr5) — Boston, MA - [Machine Learning Scientist — Large Multimodal Models (Post-Training)](https://feeny.ai/job/machine-learning-scientist-large-multimodal-models-post-training-iambic-7rzbhfe24hz9) — United Kingdom - [Machine Learning Scientist — Large Multimodal Models (Post-Training)](https://feeny.ai/job/machine-learning-scientist-large-multimodal-models-post-training-iambic-tq20zrdrpft4) — Boston, MA - [Senior / Executive Director, Analytical Development CMC](https://feeny.ai/job/senior-executive-director-analytical-development-cmc-iambic-therapeutics-inc-xc2n3pav2s88) — United States - [Associate Director / Director, Clinical Pharmacology](https://feeny.ai/job/associate-director-director-clinical-pharmacology-iambic-therapeutics-inc-san-je8hv9zyhrrm) — San Diego, CA